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Toll-like receptor 6 stimulation promotes T-helper 1
and 17 responses in gastrointestinal-associated
lymphoid tissue and modulates murine
experimental colitis
ME Morgan1, PJ Koelink1,4, B Zheng1,4, MHMGM den Brok2, HJG van de Kant1, HW Verspaget3,
G Folkerts1, GJ Adema2 and AD Kraneveld1
T-helper 1 and 17 (Th1/Th17) responses are important in inflammatory bowel disease (IBD), and research indicates that
Toll-like receptor 6 (TLR6) stimulation leads to Th17 cell development within the lung. The gastrointestinal tract, like the
lung, is a mucosal surface that is exposed to bacterially derived TLR6 ligands. Thus, we looked at the effects of TLR6
stimulation on the expression of Th17-, Th1-, and regulatory T-cell-associated transcription factors; RORct, T-bet, and
Foxp3, respectively; in CD4þ Tcells within gut-associated lymphoid tissue (GALT) in vitro and in vivo. Cells from GALT
and spleen were stimulated with anti-CD3 and TLR ligands for TLR1/2 and TLR2/6 (Pam3CSK4 and FSL-1, respectively).
FSL-1 was more effective than Pam3CSK4 at inducing Th1 and Th17 responses in the GALT while Pam3CSK4 rivaled
FSL-1 in the spleen. TLR6 was further explored in vivo using experimental colitis. Tlr6 / mice were resistant to colitis,
and oral FSL-1 led to more severe colitis in wild-type mice. Similar pro-inflammatory reactions were seen in human
peripheral blood mononuclear cells, and TLR6 expression was directly correlated with RORC mRNA levels in inflamed
intestines of IBD patients. These results demonstrate that TLR6 supports Th1- and Th17-skewed responses in the GALT
and might be an important target for the development of new medical interventions in IBD.
INTRODUCTION
Toll-like receptor 6 (TLR6) is a member of the TLR family of
pattern recognition receptors.1 Like TLR1, it forms a hetero-
dimer with TLR2.2 The heterodimer TLR2/6 recognizes
diacylated lipopeptides whereas TLR1/2 recognizes triacylated
lipopeptides.3,4 Lipopeptides are cell wall components of Gram-
positive bacteria, yeasts, and mycoplasma.
Initial studies on TLR6 have suggested that TLR2/6
stimulation on dendritic cells leads to tolerogenic dendritic
cell formation and regulatory T-cell (Treg) development.5,6
Tregs have the capacity to suppress the pro-inflammatory
activities of other immune cells, and they can differentiate into
two main groups based on their expression of the transcription
factor, forkhead box p3 (Foxp3).7 Foxp3 Treg, often known
as regulatory type 1 T cells, are induced in the periphery and
produce high amounts of interleukin (IL)-10. Foxp3þ Treg, on
the other hand, may be induced or thymus-derived and use
additional suppression mechanisms.
Recently, contradictory results were published that demon-
strated that TLR6 could support the development of T-helper
17 (Th17) cells in lung, which were protective against fungal
infection.8 Th17 cell responses are especially important for the
control of extracellular bacterial and fungal pathogens and are
particularly well known for their ability to stimulate the
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accumulation of neutrophils.9 Th17 cells are characterized by
the master transcription factor, retinoic acid-related orphan
receptor gt (RORgt) and the production of IL-17A, IL-17F,
IL-22, IL-26, tumor necrosis factor a, and granulocyte
macrophage colony-stimulating factor. Under pro-inflamma-
tory conditions, with high amounts of IL-23 and IL-1b, they
also produce interferon g (IFNg).10
Genome-wide association scan data indicate a role of Th17
cells in inflammatory bowel disease (IBD),11 and Th17 cells are
increased in patients with a magnified activation state.12–14 This
is in addition to the classical T-cell subset associations of the
two main forms of IBD: Th1 with Crohn’s disease and Th2 with
ulcerative colitis.15 Crohn’s disease, in particular, appears to be
mediated by Th1/Th17 responses,15 including highly inflam-
matory Th17 cells that produce IFNg.12,16
As TLR6 is involved in Th17 induction in the lung,8
we considered that TLR6 might be involved in modulating
Th17 responses in IBD. We found that TLR6 stimulation of
murine gut-associated lymphoid tissue (GALT) cells was more
effective than Pam3CSK4 (TLR1/2 ligand) at inducing Th1/
Th17 responses in vitro. Moreover, Tlr6 / mice were
protected against colitis while the addition of TLR6 ligands
during colitis led to worsened disease and increased Th17
responses after disease resolution. TLR6 stimulation may be
important in controlling Th1/Th17-mediated inflammation in
IBD patients.
RESULTS
TLR6 is expressed in the intestines of IBD patients and mice
with experimental colitis
Researchers have reported a role for TLR6 in the development
of Th17 cells at the lung mucosa.8 Therefore, we investigated
the expression of TLR6 mRNA and protein in inflamed
intestinal tissues. Immunofluorescence staining showed that
TLR6 was expressed in the intestine by both crypt epithelial and
non-epithelial cells, and TLR6þ cells were present in IBD
intestinal biopsies (Figure 1a). TLR6 and RORC mRNA were
also detected in both patient and control intestines (Figure 1b).
Although the mRNA levels were not significantly changed in
IBD patients, the levels of the two genes were significantly
correlated (Figure 1c), suggesting increased TLR6 expression
has a relationship with the Th17-associated master transcrip-
tion factor RORC in the intestine.
To determine Tlr6 mRNA expression in the murine colon,
we isolated mRNA from colon at both the distal (rectum) and
proximal (cecum) ends during intestinal inflammation (day 7)
in the dextran sodium sulfate (DSS)-induced colitis model. In
DSS colitis, the disease manifests more strongly at the distal
end. Although both control and DSS-treated mice expressed
Tlr6 in the colon, during colitis Tlr6 mRNA was significantly
increased in the inflamed distal region of the colon (Figure 2a).
The increased expression of TLR6 protein was confirmed by
immunoblot (Figure 2b). As expected, we observed a double
Figure 1 Toll-like receptor 6 (TLR6) is expressed during inflammatory bowel disease (IBD). (a) Immunofluorescent staining of TLR6 in intestinal tissues
obtained from a control (Control) and an IBD patient (Inflamed IBD). Negative control shows background stain without the primary antibody.
Representative stains are shown for n¼ 3 controls and IBD patients. Red staining shows TLR6þ cells, and blue shows nucleic acids (cell nuclei).
Photomicrographs were taken at  400 magnification. (b) Relative expression of RORC and TLR6 was determined for RNA obtained from colon
carcinoma patients (control, n¼10), non-inflamed regions of IBD patient intestinal tissue (non-infl-IBD, n¼ 10) and matched inflamed regions of IBD
patient intestines (infl-IBD). Data are presented as meanþ s.e.m. The measurement was performed twice independently. (c) A significant correlation was
found between the mRNA levels of RORC and TLR6 in colon samples obtained from both control and IBD patient material (n¼ 28).
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band of B100 kD, demonstrating that TLR6 is upregulated in
the colon during colitis. To determine which immune cells
express TLR6, mesenteric lymph node (MLN) cells were
isolated from control and DSS-treated mice and were examined
for TLR6 expression using flow cytometry. TLR6 expression
was low in immune cells taken from control mice (Figure 2c).
In DSS-treated mice, TLR6 expression was significantly
upregulated in CD11cþ and CD3þCD4þ cells.
TLR6 stimulation increases RORct expression in the GALT
We explored TLR1/2 and TLR2/6 stimulation in the context of
murine GALT by looking at the effect of TLR ligands (TLRLs)
on CD4þ T-cell responses in Peyer’s patches (PPs) and MLN.
Spleen was also included as a control tissue. Th17-, Th1-, and
Treg-associated responses were measured by master transcrip-
tion factor expression (RORgt, T-bet, and Foxp3, respectively).
CD4þRORgtþ T-cell expression of IL-17A was first con-
firmed in MLN cells (Figure 3a). Although not all
CD4þRORgtþ T cells expressed IL-17A (B20%), the
IL-17A expression was constrained to the CD4þRORgtþ
T-cell population.
The expression of RORgt and Foxp3 in activated CD4þ
CD69þ T cells was measured in the GALT (MLN and PP) and
spleen after stimulation with anti-CD3 and TLRLs. Stimulation
with FSL-1 in GALT cells led to a significant increase in
RORgtþ Foxp3 T cells within the CD4þCD69þ popula-
tion that was not observed in the other conditions (Figure 3b
and c). Parallel reductions in the percentage of RORgt-
Foxp3þ T cells in the FSL-1-treated GALT cells were also
noted. The effect of FSL-1 was also observed in spleen cells
(Figure 3c) and human peripheral blood mononuclear
cells (PBMCs) (Supplementary Figure 1A online).
Pam3CSK4 had little effect on GALT cells except lowering
RORgt-Foxp3þ T cells in the MLN. However, Pam3CSK4
increased the percentage of RORgtþ Foxp3 T cells in the
spleen (Figure 3c).
Loss of TLR6 expression eliminated all FSL-1-mediated
transcription factor changes (Figure 3d). Its effect on the
response caused by PAM3CSK4, in contrast, was limited.
Unlike RORgt, expression of the Th1 transcription factor,
T-bet, was not stimulated by the addition of TLRLs during the
stimulation of MLN cells with anti-CD3. It also remained
unchanged in CD4þ T cells in Tlr6 / mice (Figure 4a–d).
T-cell stimulation combined with FSL-1 increases both IFNc
and IL-17A secretion in the GALT
To further investigate influences on T-cell polarization during
stimulation with anti-CD3 and TLRLs, we measured IFNg,
IL-17A, IL-10, IL-4, IL-2, IL-6, and transforming growth factorb
(TGFb) in the supernatants after 48 h of culture. IL-4 was
hardly detectable in all of the cultures (data not shown). In
GALT cultures, the addition of FSL-1 during anti-CD3
stimulation led to significant increases in the production of
IFNg and IL-17A that were not seen after stimulation with
Pam3CSK4 (Figure 5). In PP cells, Pam3CSK4 and FSL-1 both
induced a significant increase in IL-10, a trend also seen in
MLN. FSL-1 significantly increased the levels of IL-2 in the
MLN and PP, while Pam3CSK4 had only the same response in
the MLN. Interleukin-6 was increased by both TLRLs in the
GALT, while TGFb levels remained the same in all conditions.
The spleen cells, in general, produced far higher amounts of
cytokines than the GALT cells when stimulated with anti-CD3
and TLRLs. All cytokines, except TGFb, appeared to increase.
Significant changes were measured for IFNg after FSL-1
treatment and IL-6 after Pam3CSK4 (Figure 5). Within the
spleen and human PBMCs (Supplementary Figure 1B), FSL-1
and Pam3CSK4 performed almost identically with both TLRLs
causing significant and not quite significant increases in the
cytokines tested.
FSL-1 leads to increased Th1 and Th17 cells in GALT
long-term cultures
The previous results were after short 48-h stimulations. Early
changes in transcription factor expression and cytokines may
not be representative of fully differentiated and expanded
effector T cells. Therefore, MLN and spleen cells were
stimulated with anti-CD3 in combination with the TLRLs
and expanded for 7 days in culture. Restimulation with PMA/
ionomycin revealed that both TLRLs led to significantly
Figure 2 Toll-like receptor 6 (TLR6) expression is increased during experimental colitis. (a) Distal and proximal regions of colon tissues isolated from
control and dextran sodium sulfate (DSS)-treated mice were analyzed for Tlr6 (n¼ 6). Values are presented as relative to the household gene Rps13.
(b) Immunoblot for TLR6 protein content in distal and proximal colon tissues of control and DSS-treated mice (n¼ 6). The double bands are in accordance
with the staining pattern shown by the manufacturer of the TLR6 antibody. Beta-actin staining was used as a loading control. (c) mesenteric lymph node
(MLN) cells from control and DSS-treated mice were stained (n¼4) with either an antibody for TLR6 or a matched isotype control. The percentage of
TLR6 staining was determined for various immune cells. Matched isotype values were first subtracted. Data are presented as meanþ s.e.m. P-values
considered as significant are indicated as *o0.05, **o0.01.
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increased amounts of CD4þ IL-17Aþ T cells (Th17) within
MLN cell suspensions (Figure 6a). However, FSL-1 uniquely
led to magnified percentages of CD4þ IFNgþ T cells (Th1) in
MLN cell cultures. Neither TLRL induced CD4þ IL-10þ cells.
In the spleen cell cultures, both TLRLs caused similar increases
in CD4þ IFNgþ T cells with B80% of the CD4þ T cells
expressing IFNg. Though the percentage of Th17 cells appeared
to increase in FSL-1-treated spleen cultures, only Pam3CSK4
treatment led to significant increases. Pam3CSK4 treatment
also increased the percentage of CD4þ IL-10þ T cells, while
FSL-1 decreased them.
It has been reported that CD4þ T cells double positive for
both IFNg and IL-17A are particularly potent autoimmune
Th17 cells that arise when Th17 are exposed to high IL-23 and
IL-1b.10 Therefore, we examined if the populations of CD4þ
IFNgþ IL-17Aþ T cells were also changed in the cultures.
These rare cells increased significantly in the FSL-1-treated
MLN cultures and were not affected by Pam3CSK4 treatment
(Figure 6b). In expanded spleen cultures, Pam3CSK4, but not
FSL-1 treatment, significantly increased the CD4þ IFNgþ
IL-17Aþ T-cell population.
Tlr6 / mice have lowered Th1 and Th17 responses in the
GALT and are protected against colitis
Tlr6 / mice have less Th17 cells in the lung.8 The possibility
existed that lowered Th17 numbers would be found in the
GALT as well. To determine if this was the case, T-cell subsets
were examined in the MLN and PPs of Tlr6 / mice. In both
tissues, significant reductions of CD4þRORgtþ Foxp3
T cells were observed as compared with wild-type controls
while the rest remained unchanged (Figure 7a and b). Owing to
the changes in the Th17 populations, we speculated that
Tlr6 / mice could be protected against DSS-induced colitis.
Tlr6 / mice were less susceptible to colitis than wild types,
as judged by the disease activity index (Figure 8a). This
difference was also observed in the colon length (Figure 8b).
Both Tlr6 / mice and wild-type mice had shortened colons
after DSS exposure; however, the colons of the DSS-treated wild
Figure 3 FSL-1 stimulation of murine gut-associated lymphoid tissue (GALT) cells increases RORgt expression and lowers Foxp3 expression. (a) Cells
were isolated from mesenteric lymph node (MLN) and stimulated with PMA/ionomycin (n¼6) and the numbers of IL-17Aþ cells in the CD4þRORgtþ
and CD4þRORgt- T cells population determined. Representative plots are shown for a single mouse. (b) Left column: percentages CD4þCD69þ
T cells from total MLN cells after the indicated stimulation. Right column: RORgt and Foxp3 staining of the CD4þCD69þ cells in the left column. Plots are
representative of the data presented in part c. (c) Cells isolated from the indicated lymphoid tissues from wild-type mice were stimulated with anti-CD3 and
TLRLs. Percentages of RORgtþFoxp3 and RORgt-Foxp3þ T cells were determined from the gated CD4þCD69þ T-cell population (n¼ 4, pooled
from two independent experiments). (d) Cells isolated from lymphoid tissues of Tlr6 / mice were stimulated and analyzed as in part C (n¼ 3). Data are
presented as meanþ s.e.m. P-values considered as significant are indicated as *o0.05, **o0.01 and ***o0.001.
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type mice were significantly shorter than the colons of the DSS-
treated Tlr6 / mice.
An investigation of the transcription factor expression
and cytokine production in GALT CD4þ cells revealed that
during colitis, CD4þRORgtþ Foxp3- T cells remained signi-
ficantly reduced in Tlr6 / mice compared with wild
types (Figure 8c and d). Significant and almost significant
reductions of CD4þT-betþ cells were also observed in the
MLN and PP of Tlr6 / mice. Lowered CD4þRORgt-
Foxp3þ populations were also observed in the MLN, but not in
the PP.
Oral FSL-1 increases experimental colitis severity and
residual Th17-associated responses
Because TLR6 expression was increased in the colon during
DSS colitis, we speculated that in vivo treatment with the TLR6
ligand, FSL-1, during colitis would lead to changes in the disease
progression and associated Th1 and Th17 responses. FSL-1,
Pam3CSK4, or saline in combination with ovalbumin (OVA)
were orally administered on day 4, 5, and 6 after the start of DSS
water to both healthy and DSS-treated mice (Figure 9a). Due to
the risk that oral TLRL treatment might lead to extremely severe
disease, a mild form of DSS colitis was induced. Analysis of the
weight scores showed that only FSL-1-treated mice experienced
a significantly sharper decrease in weight on day 7 as compared
with the DSS controls at these conditions (Figure 9a).
To observe changes in the T-cell compartments after
inflammation, mice were sacrificed on day 14, and cytokine
expression in CD4þ cells was examined in the MLN and
spleen. FSL-1- and DSS-treated mice had significantly increased
amounts of CD4þ IL-17Aþ cells in the MLN relative to the
mice treated with just DSS (Figure 9b). Expression of IFNgwas
low in the MLN, and no appreciable numbers of CD4þ IL-
17A-IFNgþ and CD4þ IL-17Aþ IFNgþ were noted,
preventing analysis (data not shown). Although cytokines
were measured in the spleen, there were no differences
measured between the groups (data not shown).
Further analysis of the T-cell response using anti-CD3
stimulation and transcription factor staining revealed that
FSL-1- and DSS-treated animals had approximately four times
as many potential Th17 cells within the total CD4þ T cells as
compared with the untreated DSS controls in the spleen while
Treg populations remained unchanged (Figure 9c). In the
MLNs, similar changes were observed, however, they were not
quite significant. Similar responses were also observed for
antigen-specific CD4þ T-cell responses directed against the
Figure 4 TLRL stimulation of murine mesenteric lymph node (MLN) cells does not affect T-bet expression. Wild-type (a and b) and Tlr6 / (b and c)
MLNs were stimulated with TLRLs and anti-CD3. T-bet was measured after 48 h of stimulation. None, anti-CD3 alone; PAM, Pam3CSK4 and anti-CD3;
and FSL-1, FSL-1 and anti-CD3. (a and c) Left column: percentages CD4þCD69þ T cells from total MLN cells after the indicated stimulation. Right
column: T-bet and CD4 staining of the CD4þCD69þ cells in the left column. T-bet plots are representative of the data (n¼ 5) presented in parts b and d.
Data are presented as meanþ s.e.m.
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tracking antigen OVA, which was administered simultaneously
with the TLRLs (Supplementary Figure 2).
DISCUSSION
The role of TLR6 at the mucosal interface is not well
understood. Studies by DePaolo et al.5 demonstrate that
TLR2/6 stimulation of dendritic cells, both in vitro and in vivo,
is associated with the formation of suppressive immune
responses. Recently, the same group also found lowered
regulatory responses and enhanced Th1 and Th17 responses
in TLR6 / mice6 during Yersinia enterocolitica infection,
supporting their previous findings. In contrast, research on the
lung mucosa found conflicting data. Protective Th17 responses
were impaired in TLR6 / mice during Saccharopolyspora
rectivirgula and Aspergillus fumigatus infections of the lung.8,17
Moreover, the administration of macrophage-activating lipo-
peptide-2 (another TLR2/6 ligand) to rat lung caused the influx
of immune cells.18 There are also conflicting reports about the
effects of TLR2/6 stimulation on human Treg. Some studies
show that TLR2/6 ligands suppress Treg function, like TLR1/2
ligands, while others show that it is ineffective.19,20
Our results show that there is a relationship between TLR6
stimulation in the GALT, and the induction of Th1/Th17
responses, which is not shared by TLR1/2. Even though
Pam3CSK4 stimulation leads to responses in the GALT, they
are relatively milder than those induced by FSL-1 and do not
Figure 5 T-cell stimulation with anti-CD3 and FSL-1 leads to increased IFNg, IL-17A secretion in gut-associated lymphoid tissue (GALT). Cells isolated
from murine Peyer’s patches (PPs), mesenteric lymph nodes (MLNs), and spleens were stimulated with anti-CD3 and TLRLs (n¼4). After 48 h,
supernatants were isolated and analyzed for cytokine content. The cytokines measured and the units are given in the y-axis. Data are presented as the
meanþ s.e.m. P-values considered as significant are indicated as *o0.05, **o0.01, and ***o0.001.
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support Th1. In contrast, Pam3CSK4 appears superior to FSL-1
at inducing Th1/Th17 in the spleen. Deeper investigation of
TLR6 in vivo further supported the in vitro findings for TLR6;
TLR6 stimulation worsens colitis development and is involved
with Th1/Th17 induction. Furthermore, TLR6 expression is
increased in the distal colon during colitis, where inflammation
is the highest,21 and TLR6 is expressed in the inflamed
intestines of IBD patients where it also correlates with RORC
expression. Taken together, this indicates that TLR6 is an
interesting player in intestinal inflammation.
Performing re-stimulations with anti-CD3 and TLR2/6 or
TLR1/2 ligands showed that FSL-1, but not Pam3CSK4,
induced RORgt and reduced Foxp3 in GALT cell suspensions
after 48 h of culture. As CD4þ T cells do express TLR6, this
effect could be mediated by direct signaling, or it could be
mediated by cytokine release from other immune cells. Our
results suggest that the latter could be a possibility. Th17 cells
require expression of the transcription factor, RORgt.22 Th17
differentiating conditions (anti-CD3 with low IL-2, IL-4, IFNg,
and high IL-6 and TGFb) increase Rorc mRNA after 25 h.23
In our FSL-1-treated cultures, IL-4 and IL-2 were both at low
concentrations; TGFb was present, and both IFNg and IL-6
were increased. IL-6 induces STAT3 (signal transducer and
activator of transcription 3), which is needed for Rorc
transcription.24 STAT3 also induces the loss of FOXP3 in
human natural Tregs,25 which was also observed. Despite
high concentrations of IFNg (which is not necessarily
detrimental to Th17 induction26), the environment was, at
a cytokine level, conducive to Th17 development and detri-
mental to Treg.
Despite the lack of changes in T-bet expression in GALT cells
at 48 h of culture, large amounts of IFNg were produced as well
as other pro-inflammatory cytokines. As 48 h is too short of a
period for naı̈ve T cells to be stimulated, differentiate, and
produce their own cytokines; the source must be other cells
found in our cell suspensions. Existing memory Th1 cells are
likely candidates, and it is known that they produce IFNg and
IL-10 when costimulated with TLR2 ligands.27 Other options
Figure 6 FSL-1 leads to increased Th1 and Th17 cells in extended mesenteric lymph node (MLN) cultures. Cells isolated from the MLNs or spleens
(n¼ 4) were stimulated with anti-CD3 and TLRLs for 7 days followed by PMA/ionomycin stimulation. (a) Percentages of cytokine-positive CD4þ cells are
indicated. (b) Percentages of CD4þ IFNgþ IL-17Aþ cells are shown in the column figure on the right. Representative FACS plots for a single mouse are
also shown. Data in column graphs are presented as the meanþ s.e.m. P-values considered as significant are indicated as *o0.05, **o0.01, and
***o0.001.
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are memory CD8þ T cells,28 innate lymphoid cells,29 dendritic
cells,30 and macrophages.31
To further determine the long-term effects on T-cell
differentiation, extended cultures were performed with the
TLRLs. In MLNs, Pam3CSK4 induced CD4þ IL-17Aþ cells
just as well as FSL-1 but, unlike FSL-1, did not induce CD4þ
IFNgþ cells. Looking at the cytokines produced during the first
48 h shows that MLN stimulated with anti-CD3 and Pam3CSK4
produced significantly higher levels of IL-6. As IL-6 combined
with TGFb is needed to differentiate Th17 cells, the development
of Th17 is to be expected. The response is not, however, entirely
the same as that with FSL-1, which also induced IFNg/IL-17A
double-positive cells. These cells are indicative of a highly pro-
inflammatory cytokine milieu and promote intestinal inflam-
mation found in IBD.12,16 The main difference between the two
stimulations was the presence of IFNg in the FSL-1 cultures. The
presence of IFNg supports Th1 development32 and also
promotes Th17 responses.26 This could be the main reason
that FSL-1 leads to Th1/Th17 responses in the GALT.
We observed clear differences between Pam3CSK4 and
FSL-1 in the GALT. This does not exclude an important role for
TLR1/2 in intestinal inflammation, but does suggest that it is
different than that of TLR2/6. Our results and studies by
DePaolo et al.6 indicate that TLR1/2 is responsible for intestinal
Th17 responses. Still, TLR1/2 stimulation is more potent in the
spleen than GALT, inducing both Th1 and Th17. This tissue
specific response is an important consideration for future work
on TLRLs and may offer some explanation to conflicting data in
previous publications.
To investigate TLR6 in intestinal inflammation, DSS colitis
was induced in Tlr6 / mice. Our experiments showed that
these mice were partially protected from the disease. Inter-
estingly, Tlr6 / mice have reduced numbers of Th17 cells as
compared with the wild-type mice, and they remain low even
during colitis. During colitis, these mice also had fewer CD4þ
T-betþ cells and reduced Treg. Although the loss of Treg is
puzzling, the reductions in Th1/Th17 may have influenced the
severity of disease.
To learn more about the fate of CD4þ T cells primed during
DSS-induced colitis, FSL-1 or Pam3CSK4 were orally admi-
nistered along with the tracking antigen OVA during the
induction of colitis in wild-type animals. Significantly increased
Th17 responses in the FSL-1- and DSS-treated mice were
found in the MLNs and spleen using several different
assays. This is particularly striking as these responses were
measured 7 days after DSS treatment was stopped. In contrast,
residual Th1 responses were not measured. DSS colitis-
associated T-cell responses within the spleen after disease
resolution are not unusual. It has been observed that after DSS
colitis heals, there is a striking increase of CD4þ T cells in the
spleen, while the percentage of T cells within the MLN
normalizes,33 which may also explain why the percentages of
Figure 7 Tlr6 / mice have lower amounts of CD4þRORgtþ cells. (a) Gut-associated lymphoid tissue (GALT) cells were isolated from both
Tlr6 / and wild-type mice (n¼ 6). RORgt, Foxp3, and T-bet expression were analyzed within the CD4þ T-cell population. (b) Representative plots of
a single mouse are shown for the transcription factor staining. Data are given as meanþ s.e.m. P-values considered as significant are indicated as
*o0.05. PPs, Peyer’s patches.
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cytokine-expressing T cells was so low in our intracellular
cytokine staining assay.
Our results point to TLR6 being an important driver of Th1
and Th17 responses in the GALT. This is supported by both
in vitro and in vivo evidence. Moreover, the fact that RORC and
TLR6 mRNA levels are correlated in human intestine and that
stimulations of human PBMCs mimic the murine results,
suggests a similar relationship between TLR6 and pro-
inflammatory T-cell polarization in humans. As the reduction
of Th1/Th17 responses in IBD is a prime goal for therapy, TLR6
could be a potential target for future IBD treatments.
METHODS
Animals. Female C57BL/6 mice for the oral TLRL study and for the
in vitro experiments were purchased from Charles River Laboratories
(Maastricht, The Netherlands). The mice were used at 8–12 weeks of
age and were housed under standard conditions in the animal facilities
at Utrecht University. Breeding pairs of Tlr6 / mice were obtained
from Shizuo Akira (Osaka University). Male and female Tlr6 /
mice used both in vivo and in vitro were bred and kept in standard
conditions at the Central Animal Facility of the Radboud University
Nijmegen Medical Centre. Sex and aged-matched C57BL/6 controls
used in the Tlr6 / in vivo experiment were bred in the same locale
as the Tlr6 / mice.
Experimental colitis. Experimental colitis was induced in all mice by
adding 1.5% (w/v) DSS (MP Biomedicals LLC, Illkirch, France) to the
drinking water of the mice for 6 days, starting at day 1 of the
experiment. Mice were sacrificed on either day 7 or 14 after starting
DSS, depending on the experiment. Individual mice were considered a
single experimental unit.
Oral gavages for TLRLs and OVA administration were performed
on day 4, 5, and 6 to coincide with the developing intestinal
inflammation. Each gavage contained 400mg endotoxin-free OVA
(Hyglos GmBH, Bernried am Starnberger See, Germany) and 80 mg of
Figure 8 Tlr6 / mice have reduced Th1 and Th17 responses and are protected from colitis. (a) Disease activity index (DAI) is shown for healthy
controls and dextran sodium sulfate (DSS)-treated wild-type and Tlr6 / mice (n¼ 6). (b) In the same mice, colon lengths were measured at sacrifice
(day 7 after start of DSS). (c) Transcription factor staining is shown for CD4þ T cells from the gut-associated lymphoid tissue (GALT) for the mice in the
above experiment treated with DSS. (d) Representative FACS plots are shown for the data presented in c. Data are given as meanþ s.e.m. P-values
considered as significant are indicated as *o0.05, **o0.01, ***o0.001, and ****o0.0001. MLN, mesenteric lymph node; PPs, Peyer’s patches.
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either Pam3CSK4 or FSL-1 (both from EMC microcollections,
Tuebingen, Germany) in 500 ml saline solution. Both FSL-1 and
Pam3CSK4 are synthetic lipopeptides. Control animals were admi-
nistered saline only.
The disease activity index of colitis was determined by combining
the scores collected from the weight measurement, rectal condition, feces
condition, and the detectable presence of blood in the feces. The disease
activity index was between 0 and 11 for each mouse. The loss of weight was
scored as follows relative to starting weight: 0, 0–2.5% weight loss; 1, 2.5–
5% weight loss; 2, 5–10% weight loss; 3, 10–15% weight loss; and 4,415%
weight loss. The feces condition score was scored as follows: 0, normal; 1,
soft with normal form; 2, loss of form/diarrhea; and 3, no feces produced.
The rectal condition score was determined as follows: 0, normal; 1,
irritation present; 2, mucus and/or swelling; and 3, visible blood. Fecal
blood was tested with a Colo-rectal test kit (Axon Lab AG, Stuttgart,
Germany). Fecal blood was scored as follows: 0, no blood; 1, blood.
Messenger RNA expression analysis. The human intestinal tissue
samples in this study were obtained from surgical resection specimens
and include pairs of macroscopically inflamed and normal-appearing
(non-inflamed) mucosa from patients with Crohn’s disease (n¼ 5)
and ulcerative colitis (n¼ 5), both clinically and histologically con-
firmed, with normal tissue from patients with a colorectal carcinoma,
at least 10 cm from the tumor, as controls. Details on the tissue
specimens and patient characteristics are described in a previous study
as well as the methods of total RNA isolation.34
For the murine colon samples, the colons were divided into two
equal sections: proximal and distal. The total RNA was isolated using
the RNAeasy kit (Qiagen, Germantown, MD) and, subsequently,
reverse transcribed into cDNA using the iScript cDNA synthesis kit
(BioRad, Hercules, CA).
Real-time PCR was performed using iQ SYBR Green super mix kit
(BioRad) with the CFX 96 Real-time system (BioRad). Messenger RNA
Figure 9 Oral FSL-1 worsens colitis and increases the Th17 response. Mice were administered regular water or dextran sodium sulfate (DSS) water for
6 days. On day 4, 5, and 6, mice were given oral TLRLs combined with the tracking antigen ovalbumin (OVA). One week after stopping DSS, the mice were
sacrificed (n¼ 5). (a) Percent weight gain of the mice over time relative to starting weight. Data are shown as the mean of each day þ / s.e.m. The
experimental design is shown under the weight graph. (b) Intracellular cytokine staining on CD4-gated mesenteric lymph node (MLN) cells isolated from
the in vivo experiment. Data are presented as relative values of the mean percentage staining found in the untreated group (the group not receiving TLRL
treatment). FACS plots on the right show representative staining of the DSS samples. (c) MLN and spleen cell cultures were analyzed for percentages of
RORgtþFoxp3 (Th17) and RORgt-Foxp3þ (Treg) T-cell populations in CD4þ T cells after 48 h of anti-CD3 stimulation. Data are presented in the
same manner as b. Representative FACS plots on the right show examples of spleen data. Data are shown as the meanþ s.e.m. P-values considered as
significant are indicated as *o0.05, **o0.01, ***o0.001, and ****o0.0001.
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for ribosomal protein S13 (RPS13) was used as the internal control in
mice, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA was used as the internal control in the human samples. The
primers used for the human real-time PCR were obtained from SA
Biosciences (Frederick, MD). The primer sequences used for the
mouse studies were as follows: Tlr6 fwd: 50 GACTCTCCCACAAC
AGGATACG 30, Tlr6 rev: 50 TCAGGTTGCCAAATTCCTTACAC 30,
Rps13 fwd: 50 GTCCGAAAGCACCTTGAGAG 30, Rps13 rev: 50
AGCAGAGGCTGTGGATGACT 30. The final data for the target
samples were normalized against the internal control GAPDH in the
human samples and Rps13 in the mouse samples. The relative mRNA
expression values were calculated using Bio-Rad CFX manager V1.6.
Immunofluorescence. Cryostat sections (5 mm) of the intestinal
tissues of CD patients (n¼ 5), UC patients (n¼ 5) and normal tissue
from patients with a colorectal carcinoma (n¼ 5) were cut, fixed in ice-
cold acetone for 10 min, blocked with 5% goat serum in 1% BSA/PBS
(bovine serum albumin/phosphate-buffered saline) and afterwards
incubated with rabbit-anti-TLR6 (1:125, Novus Biologicals,
Cambridge, UK, NBP1-54336) in 1% BSA/PBS overnight at 4 1C. After
subsequent washings with PBS, the antibodies were visualized by
incubation with goat-anti-rabbit-Alexa568 (1:400, Invitrogen, Breda,
The Netherlands) in 1% BSA/PBS for 1 h at room temperature.
Counterstaining was done with Hoechst 33,342 (Sigma Aldrich
Chemie BV, Zwijndrecht, The Netherlands) for 5 min at room
temperature and slides were sealed with Prolong gold anti-fade reagent
(Invitrogen). Photomicrographs were taken at room temperature with
an Olympus BX-60 microscope with a  40/0.75na objective lens
equipped with a Leica DFC425 C camera and controlled with LAS
software 4.0.
Ex vivo T-cell stimulation and PBMC culture. PPs, MLN, and
splenocytes were isolated from mice. Cells were re-stimulated with
either 25 mg ml l endotoxin-free OVA (Hyglos GmBH) or 2 mg ml l
anti-CD3 (eBioscience, San Diego, CA) with or without Pam3CSK4 or
FSL-1 (4mg ml l; EMC microcollections) and cultured with RPMI
medium (Roswell Park Memorial Institute medium, Life Technologies,
Paisley, Scotland) supplemented with 1 unit per ml penicillin,
1 mg ml l streptomycin, 50 mM b-mercaptoethanol, and 5% FCS in 96-
well round-bottom plates at a concentration of 105 cells per well.
During the long stimulation, cells were incubated for 7 days before
restimulation with PMA/ionomycin (Sigma). Otherwise, cells were
incubated for 48 h, after which, supernatants were collected; cells were
harvested and stained with fluorescently labeled antibodies.
Human PBMCs were cultured in RPMI medium supplemented with
1 unit per ml penicillin, 1 mg ml l streptomycin, 1 mM pyruvate,
50 mg ml l gentamicin, and 2.5% FCS in 96-well round-bottom
plates at a concentration of 105 cells per well. Similarly to the murine
experiments, the cells were incubated for 48 h with anti-CD3
(1mg ml l; eBioscience) with or without TLRLs (Pam3CSK4 or
FSL-1, 4 mg ml l; EMC microcollections). Upon completion of the
incubation, the supernatants were collected and the cells harvested for
FACS staining.
Flow cytometry. Intracellular cytokine staining was performed on
either fresh or cultured cells after 5 h stimulation with PMA/Iono-
mycin (Sigma) and Brefeldin A (eBioscience). Cells were then stained
with antibodies for CD4, IFNg, IL-17A, IL-10, and IL-4 (all antibodies
from eBioscience) using the Foxp3 intracellular staining kit
(eBioscience). To prevent background staining, cells were first
incubated with unlabeled anti-CD16/32 (eBioscience) for 15 min on
ice as suggested in the manufacturer’s protocol. Fixed samples were
kept at 4 1C until reading with the flow cytometer.
Transcription factor expression was measured in murine cells or
PBMCs by performing a surface stain with anti-CD4 and anti-CD69
and then staining intracellularly for Foxp3, T-bet, and RORgt.
All antibodies and the Foxp3 intracellular staining reagents were
obtained from eBioscience. Before the surface stain and again
during the intracellular stain, samples were blocked with unlabeled
anti-human/mouse CD16/32 (eBioscience) for 15 min on ice. Fixed
samples were kept at 4 1C until reading with the flow cytometer. All
samples were read on a FACSCanto II flow cytometer (BD Biosciences,
San Jose, CA) and analysis of the flow cytometry data was performed
using BD FACSDiva software (BD Biosciences).
Cytokine measurements. Isolated supernatants were analyzed for
cytokine production by using either the human or mouse BD
Cytometric Bead Array Th1/Th2/Th17 kits (BD Biosciences) and the
mouse/human TGFb Ready-Set-Go! ELISA from eBioscience. Kits
were used according to manufacturer’s protocol. The bead array
samples were read using a FACSCanto II flow cytometer (BD
Biosciences). Data analysis was performed using the FCAP Array
Analysis software and FCS Filter Software (Soft Flow Hungary Ltd.,
Pecs, Hungary).
Immunoblot. Intestinal tissues were weighed (100 mg ml l) and
homogenized in radioimmunoprecipitation assay buffer containing
protease inhibitors and EDTA (Thermo Fisher Scientific, Rockford,
IL) using a Precellys 24 tissue homogenizer (Bertin Technologies,
Montigny-le-Bretonneux, France) for four times 10 s at 6,000 rpm with
a minimum 5 min cooling period on ice in between. Afterwards,
samples were centrifuged for 15 min at 14,000 rpm and the super-
natant was transferred to a clean tube. Homogenates were separated on
4–20% (w/v) SDS gels (BioRad) and blotted to nitrocellulose
membranes (Millipore, Billerica, MA). Membranes were blocked for
2 h with 5% milk proteins in PBS/0.1% Tween-20 and subsequently
incubated with rabbit-anti-mouse TLR6 (Sigma, SAB1300203) in PBS/
2% milk/0.1% Tween-20 overnight at 4 1C. After incubation,
membranes were washed three times with PBS/2% milk/0.1% Tween-
20, incubated with goat-anti-rabbit-horse radish peroxidase (Dako,
Heverlee, The Netherlands) in PBS/2% milk/0.1% Tween-20, treated
with commercial ECL reagents (Amersham Biosciences, Roosendaal,
The Netherlands) and finally exposed to photographic film. After-
wards, blots were stripped with stripping buffer (Thermo Fisher
Scientific) and reprobed with rabbit-anti-b-actin (Cell Signaling
Technology, Danvers, MA). The TLR6 staining appears as double
bands and this is in accordance with the staining pattern depicted by
the manufacturer.
Statistical analysis. Means with s.e.m. are represented in each graph.
Statistical analysis was performed using GraphPad Prism version 6.0
for windows (GraphPad Software, San Diego, CA). Correlation
significance was determined using the Pearson product–moment
correlation coefficient. For comparisons between two groups, T-test or
Mann–Whitney test were used depending on the distribution of the
data. Comparisons between three or more groups were performed with
either a one-way analysis of variance or repeated measures analysis of
variance followed by the Bonferroni post test where appropriate. In
cases of repeated, nonparametric data, the Friedman test followed by
Dunn’s multiple comparison post test was used. In the situation of two
independent parameters, a two-way analysis of variance was applied
(either regular or repeated measures) with the Bonferroni post test.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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